Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 4, 2016, Pages 597-609

  Marotta, P ^a   Bailey, R ^b   Elkashab, M ^c   Farley, J ^d   Feinman, S V ^e   Peltekian, K ^f   Poliquin, M ^g   Witt Sullivan, H ^h   Rampakakis, E ⁱ   Drolet, M ^j   Cooper, C ^k  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Toronto Liver Centre   (Canada)

^d Dr John Farley Inc   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f Atlantic Hepatology Services   (Canada)

^g Clinique Medicale l'Actuel   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ JSS Medical Research Inc   (Canada)

^j Merck Canada Inc   (Canada)

^k OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AGED; CANADA; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CANADA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957565069     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2576-1     Document Type: Article

References (59)

1. World Health Organization (WHO) (2010) Resolutions from the Sixty-third World Health Assembly (WHA63). WHO
2. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17(2):107–115
3. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K et al (2014) Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 28(5):243–250
4. Zou S, Tepper M, El Saadany S (2000) Prediction of hepatitis C burden in Canada. Can J Gastroenterol 14(7):575–580
5. Public Health Agency of Canada (PHAC) (2009) Epidemiology of acute hepatitis C infection in Canada: results from the Enhanced Hepatitis Strain Surveillance System (EHSSS)
6. Amarapurkar D (2000) Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 15(Suppl):E105–E110
7. Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C et al (2008) Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 15(1):52–57
8. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S et al (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38(1):75–85
9. Mihm S, Fayyazi A, Hartmann H, Ramadori G (1997) Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25(3):735–739
10. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F (2006) Steatosis in chronic hepatitis C: why does it really matter? Gut 55(1):123–130
11. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T et al (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2):522–527
12. Brown RS Jr, Jacobson IM, Afdhal N, Freilich B, Pauley BP, Regenstein F, Flamm S, Kwo P, Griffel L, Brass CA, and the WIN-R Study Group (2006) Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis c genotypes 2 and 3 in the WIN-R Trial. Abstract 41, EASL
13. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J et al (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40(6):993–999
14. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28(4):397–404
15. Lange CM, Jacobson IM, Rice CM, Zeuzem S (2014) Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 6(1):4–15
16. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346–355
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965
18. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ (2012) An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the study of the liver. Can J Gastroenterol 26(6):359–375
19. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR et al (2012) Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 107(5):669–689; quiz 690
20. Pawlotsky J (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60(2):392–420
21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887
22. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867–1877
23. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia ES, Brainard DM, Symonds WT, Hutchinson JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R (2013) Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Abstract 10-15-2013b;733A. Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013, Washington, DC, November 2013
24. American Association for the Study of Liver Diseases (AASLD) (2014) Recommendations for testing, managing, and treating hepatitis C
25. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ (2015) An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 29(1):19–34
26. Chhatwal J, Kanwal F, Roberts MS, Dunn MA (2015) Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162(6):397–406
27. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR et al (2015) The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 162(9):619–629
28. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T et al (2015) Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 162(6):407–419
29. San Miguel R, Gimeno-Ballester V, Blázquez A, Mar J (2015) Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 64(8):1277–1288
30. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R et al (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357(2):124–134
31. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138):1426–1432
32. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492
33. Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H et al (2011) Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 55(3):554–563
34. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M et al (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352(25):2609–2617
35. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975–982
36. Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K et al (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47(6):1837–1845
37. Aghemo A, Rumi MG, Soffredini R, D’Ambrosio R, Ronchi G, Del Ninno E et al (2006) Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 11(6):797–802
38. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S et al (2006) Higher clearance of hepatitis C virus infection in females compared with males. Gut 55(8):1183–1187
39. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59(1):109–120
40. Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340(16):1228–1233
41. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP et al (2007) Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 196(10):1474–1482
42. Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H et al (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 43(4):590–598
43. Deuffic-Burban S, Poynard T, Valleron AJ (2002) Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 9(2):114–122
44. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055):825–832
45. Villa E, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A et al (2011) Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 140(3):818–829
46. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C et al (2003) Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 52(4):574–579
47. Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F et al (2004) Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 40(6):1426–1433
48. Villa E, Vukotic R, Cammà C, Petta S, Di Leo A, Gitto S et al (2012) Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One 7(9):e44624
49. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158(2):177–181
50. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405–2416
51. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N et al (2007) Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 21(Suppl C):25C–34C
52. Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE (2012) Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-alpha-2a plus ribavirin and RVR. J Viral Hepat 19(5):346–352
53. Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S et al (2011) Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 9(8):688–693
54. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401
55. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105–1109
56. Berg T, Carosi G (2008) Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther 13(Suppl 1):17–22
57. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22(6):832–836
58. Hepatitis C Education and Prevention Society (HEPCBC) (2015) Updates to Canadian sofosbuvir pricing and CADTH queuing schedule. October 8th, 2014
59. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N et al (2004) Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 22(4):257–265